Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

John Mascarenhas, Andrew Kuykendall, Terrence Bradley, Bart Scott, Habte Yimer, Yiqun Yang, Fei Huang, Ying Wan, Shyamala Navada, Judy Ho, Tymara Berry, Salman Otoukesh

Blood (2025) 146 (Supplement 1): 2052.

https://doi.org/10.1182/blood-2025-2052

Published: 2025

Journal Articles

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Amandeep Salhotra, Jamie Wagner, Dongyun Yang, Haris Ali, Salman Otoukesh, Jemily Juan, Sindhu Saraswathy, Isaac Garcia, Dileshni Tilakawardane, Sunmin Park, Stephen Forman, Ryotaro Nakamura, Christine Brown, Enrique Montero

Blood (2025) 146 (Supplement 1): 276.

https://doi.org/10.1182/blood-2025-276

Published: 2025

Journal Articles

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation

Dat Ngo, Jose Tinajero, Karamjeet Sandhu, Idoroenyi Amanam, Salman Otoukesh, Shukaib Arslan, Sunmin Park, Haris Ali, Badri Modi, Ryotaro Nakamura, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 7612.

https://doi.org/10.1182/blood-2025-7612

Published: 2025

Journal Articles

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Klara Kim, Dat Ngo, Jose Tinajero, Dongyun Yang, Haoyue Shan, Karamjeet Sandhu, Haris Ali, Salman Otoukesh, Idoroenyi Amanam, Shukaib Arslan, Vaibhav Agrawal, Sunmin Park, Ryotaro Nakamura, Monzr M. Al Malki, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 935.

https://doi.org/10.1182/blood-2025-935

Published: 2025

Journal Articles

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Blood (2025) 146 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2025-1684

Published: 2025

Journal Articles

Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis

Salman Otoukesh, Brian Ball, Dongyun Yang, Ketevan Gendzekhadze, Karamjeet Sandhu, Shukaib Arslan, Amanda Blackmon, Pamela Becker, Firoozeh Sahebi, Anna Pawlowska, Monzr M. Al Malki, Michelle Afkhami, Stephen Forman, Guido Marcucci, Vinod Pullarkat, Raju Pillai, Ryotaro Nakamura

Blood (2025) 146 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2025-1431

Published: 2025

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Blood (2025) 146 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2025-4305

Published: 2025

Journal Articles

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Blood (2025) 146 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2025-2464

Published: 2025

Journal Articles

Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis

Monzr M. Al Malki, Dongyun Yang, Sally Mokhtari, Anissa Bailey, Pooja Rajeevan, Rhiannon Imbeah, Salman Otoukesh, Brian Ball, Paul Koller, Vaibhav Agrawal, Yazeed Samara, Firoozeh Sahebi, Ibrahim Aldoss, Andrew Artz, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Haris Ali

Blood (2025) 146 (Supplement 1): 2455.

https://doi.org/10.1182/blood-2025-2455

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Monzr M. Al Malki, Susanta Hui, Dongyun Yang, Sally Mokhtari, Hoda Pourhassan, Matthew Mei, Amanda Blackmon, Firoozeh Sahebi, Amandeep Salhotra, Brian Ball, Shukaib Arslan, Salman Otoukesh, Haris Ali, Guido Marcucci, Ryotaro Nakamura, Stephen Forman, Anthony Selwyn Stein, Jeffrey Wong

Blood (2025) 146 (Supplement 1): 376.

https://doi.org/10.1182/blood-2025-376

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Blood (2025) 146 (Supplement 1): 2516.

https://doi.org/10.1182/blood-2025-2516

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Blood (2025) 146 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2025-4282

Published: 2025

Journal Articles

Cytokine profiling identifies an IL‑8/IL1RAP‑Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms (MPN) associated with high symptom burden and poor outcomes

Idoroenyi Amanam, Lucy Ghoda, Salman Otoukesh, Yile Zhou, Bin Zhang, Dauh-Lian Chi, Tim Synold, John Williams, Monzr M. Al Malki, Haris Ali, Guido Marcucci

Blood (2025) 146 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2025-5593

Published: 2025

Journal Articles

Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Idoroenyi Amanam, Lucy Ghoda, Monzr M. Al Malki, Karamjeet Sandhu, Andrew Artz, Amanda Blackmon, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Salman Otoukesh, Haris Ali

Blood (2025) 146 (Supplement 1): 5592.

https://doi.org/10.1182/blood-2025-5592

Published: 2025

Journal Articles

Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Idoroenyi Amanam, Lucy Ghoda, Salman Otoukesh, Andrew Artz, Amanda Blackmon, Karamjeet Sandhu, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Monzr M. Al Malki, Haris Ali

Blood (2025) 146 (Supplement 1): 5591.

https://doi.org/10.1182/blood-2025-5591

Published: 2025

Journal Articles

Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)

John O. Mascarenhas, Salman Otoukesh, Terrence Bradley, Bart L. Scott, Habte A. Yimer, Souria Dougherty, Lixian Peng, Fei Huang, Ying Wan, Faye M. Feller, Vivian Rodolf, Judy Ho, Tymara Berry, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 998.

https://doi.org/10.1182/blood-2024-203800

Published: 2024

Journal Articles

TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2024) 144 (Supplement 1): 729.

https://doi.org/10.1182/blood-2024-208674

Published: 2024

Journal Articles

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Blood (2024) 144 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2024-206169

Published: 2024

Journal Articles

Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Blood (2024) 144 (Supplement 1): 4935.

https://doi.org/10.1182/blood-2024-210956

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Cytokine profiling identifies an IL‑8/IL1RAP‑Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms (MPN) associated with high symptom burden and poor outcomes

Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only